Clinic Cardiovascular Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona , Barcelona, Spain.
Expert Rev Med Devices. 2020 Jul;17(7):671-682. doi: 10.1080/17434440.2020.1784005. Epub 2020 Jun 30.
Coronary percutaneous interventions have evolved from plain old balloon angioplasty (POBA) to stent implantation, which itself evolved from bare-metal stents (BMS) to the new biodegradable stents which try to restore endothelial function. Currently, the most commonly used stent is the everolimus-eluting stent.
This review will cover the current status of durable polymer everolimus-eluting stent, its history, and future perspectives. Nowadays, the everolimus-eluting stent is the most used device in the acute and chronic settings due to its safety and efficacy.
Durable polymer everolimus-eluting stent, supported by much evidence, has demonstrated its efficacy and safety, not only in de novo artery lesions, but in multiples scenarios, such as the acute setting and diabetic population, becoming one of the most polyvalent stents available. Nowadays, research is focused on the reduction of antiplatelet treatment duration. Similar rates of stent thrombosis with short dual antiplatelet treatment regimens of 1 to 3 months compared to pronged treatment have been observed. However, specific studies should be performed to evaluate this possibility.
经皮冠状动脉介入治疗已从单纯的球囊血管成形术（POBA）发展到支架植入术，支架本身也从裸金属支架（BMS）发展到试图恢复内皮功能的新型可生物降解支架。目前，最常用的支架是依维莫司洗脱支架。
本综述将涵盖目前持久聚合物依维莫司洗脱支架的现状、历史和未来展望。如今，由于其安全性和疗效，依维莫司洗脱支架在急性和慢性环境中是使用最广泛的器械。
持久聚合物依维莫司洗脱支架得到了大量证据的支持，不仅在新发病变的动脉中，而且在多种情况下，如急性环境和糖尿病患者中，都证明了其疗效和安全性，成为目前应用最广泛的多用途支架之一。如今，研究的重点是减少抗血小板治疗的持续时间。与延长抗血小板治疗相比，观察到 1 至 3 个月的短双联抗血小板治疗方案与支架血栓形成的发生率相似。然而，应进行具体的研究来评估这种可能性。
